Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma
2014 ASH Annual MeetingLaurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.
Related Videos
Keith McCrae, MD, on Splenectomy in Immune Thrombocytopenia
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 232, “Long-Term Comp...
Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, T...
James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinic...
Richard M. Stone, MD, on the SWOG S1117 Study
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract LBA-5, “...
Sagar Lonial, MD, on the Phase III ASPIRE Trial
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 79, “Carfilzomib...
